The efficacy of Botulinum Toxin A in poststroke spasticity
| Autor: | Şimşir Atalay, N., Akkaya, N., Özlü, A., Şahin, F. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
drug safety
Modified Ashworth Scale hemiplegia Functional Independence Measure rivermead motor assessment functional status Fugi Meyer finger Botulinum toxin human hand function mobilization clinical assessment tool elbow flexion clinical article muscle function adult article spasticity treatment response arm muscle body regions drug efficacy leg muscle quality of life Short Form 36 arm disease motor performance leg disease functional assessment neurophysiology botulinum toxin A physical disease rating scale |
| Popis: | To assess the efficacy of the Botulinum Toxin A (BTX-A) on spasticity, motor evaluation, function and quality of life in patients with spasticity of upper and lower extremity following hemiplegia. Spasticity was assessed with Modified Ashworth Scale (MAS), motor function of upper and lower extremities and hand of hemiplegic side were evaluated with Brunnstrom neurophysiologic evaluation, mobilization was assessed with Rivermead Motor Assessment (RMA), upper extremity function was evaluated with Fugl Meyer (FM), functional assesment was evaluated with Functional Independence Measure (FIM), quality of life was assessed with Short Form 36 (SF-36) at baseline and at week 6. Sixteen patients (4 right hemiplegia, 12 left hemiplegia) with mean age of 47.56±17.2 years were included. BTX-A was injected into the forearm flexors in 7 cases, pronators in 6 cases, wrist flexors in 6 cases, finger flexors in 10 cases, and ankle flexors in 8 cases with a total dose of 300 U for each case. Significant improvements were detected for MAS of all muscles which were BTX-A injected compared to pretreatment. Significant improvements were detected for Brunnstrom evaluation of hand, RMA, FM and FIM compared to pretreatment. While significant improvement was found for only role limitations due to physical problems subgroup of SF-36, there was no statistical difference for other subgroups. Botulinum toxin A is safe regarding side effects, and improves the functional capacity of patient in the treatment of spasticity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|